Book contents
- Management of Complex Treatment-Resistant Psychotic Disorders
- Management of Complex Treatment-Resistant Psychotic Disorders
- Copyright page
- Contents
- Contributors
- Acknowledgements
- Abbreviations
- List of Icons
- Introduction
- Part I Treatment Strategies
- Part II Medication Reference Tables
- Appendices
- 3.01 Appendix Optimal Antipsychotic Plasma Concentration Ranges [–]
- 3.02 Appendix Optimal Mood Stabilizer Plasma Concentration Ranges [, ]
- 3.03 Appendix Formulas for Correcting QT Interval [, ]
- 3.04 Appendix Common Cytochrome P450 Inducers and Inhibitors [, ]
- 3.05 Appendix Management of Constipation [, ]
- 3.06 Appendix Child-Pugh Hepatic Function Scoring [, ]
- 3.07 Appendix Loading of Lithium and Valproic Acid [–]
- 3.08 Appendix Treatment of Prolactin Elevation [–]
- 3.09 Appendix A Select List of Foods High in Tyramine [–]
- 3.10 Appendix Medications That Present Risk for Serotonin Syndrome When Combined with Monoamine Oxidase Inhibitor [–]
- 3.11 Appendix Selected Treatment of Psychomotor Agitation Algorithm [–]
- Index
- References
3.11 Appendix - Selected Treatment of Psychomotor Agitation Algorithm [–]
from Appendices
Published online by Cambridge University Press: 19 October 2021
Book contents
- Management of Complex Treatment-Resistant Psychotic Disorders
- Management of Complex Treatment-Resistant Psychotic Disorders
- Copyright page
- Contents
- Contributors
- Acknowledgements
- Abbreviations
- List of Icons
- Introduction
- Part I Treatment Strategies
- Part II Medication Reference Tables
- Appendices
- 3.01 Appendix Optimal Antipsychotic Plasma Concentration Ranges [–]
- 3.02 Appendix Optimal Mood Stabilizer Plasma Concentration Ranges [, ]
- 3.03 Appendix Formulas for Correcting QT Interval [, ]
- 3.04 Appendix Common Cytochrome P450 Inducers and Inhibitors [, ]
- 3.05 Appendix Management of Constipation [, ]
- 3.06 Appendix Child-Pugh Hepatic Function Scoring [, ]
- 3.07 Appendix Loading of Lithium and Valproic Acid [–]
- 3.08 Appendix Treatment of Prolactin Elevation [–]
- 3.09 Appendix A Select List of Foods High in Tyramine [–]
- 3.10 Appendix Medications That Present Risk for Serotonin Syndrome When Combined with Monoamine Oxidase Inhibitor [–]
- 3.11 Appendix Selected Treatment of Psychomotor Agitation Algorithm [–]
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Management of Complex Treatment-resistant Psychotic Disorders , pp. 502 - 507Publisher: Cambridge University PressPrint publication year: 2021
References
Smith, D., Smith, R., Misquitta, D. (2016). Neuroimaging and violence. Psychiatr Clin North Am, 39, 579–597.CrossRefGoogle ScholarPubMed
Davidson, L. L., Heinrichs, R. W. (2003). Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res, 122, 69–87.CrossRefGoogle ScholarPubMed
Hill, K., Mann, L., Laws, K. R., et al. (2004). Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand, 110, 243–256.CrossRefGoogle ScholarPubMed
Sripada, C. S., Silk, K. R. (2007). The role of functional neuroimaging in exploring the overlap between borderline personality disorder and bipolar disorder. Curr Psychiatry Rep, 9, 40–45.CrossRefGoogle ScholarPubMed
McDermott, B. E., Holoyda, B. J. (2014). Assessment of aggression in inpatient settings. CNS Spectr, 19, 425–431.CrossRefGoogle ScholarPubMed
Poldrack, R. A., Monahan, J., Imrey, P. B., et al. (2018). Predicting violent behavior: what can neuroscience add? Trends Cogn Sci, 22, 111–123.CrossRefGoogle ScholarPubMed
Stahl, S. M., Morrissette, D. A., Cummings, M., et al. (2014). California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr, 19, 449–465.CrossRefGoogle ScholarPubMed
Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.CrossRefGoogle ScholarPubMed
Morrissette, D. A., Stahl, S. M. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr, 19, 439–448.CrossRefGoogle ScholarPubMed
Cummings, M. A., Proctor, G. J., Arias, A. W. (2019). Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectr, in press, doi: 10.1017/S1092852919000841CrossRefGoogle Scholar
Citrome, L., Volavka, J. (2011). Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs, 25, 1009–1021.CrossRefGoogle ScholarPubMed
Correll, C. U., Yu, X., Xiang, Y., et al. (2017). Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry, 29, 92–107.Google ScholarPubMed
Levy, R. H., Friel, P. N., Johno, I., et al. (1984). Filtration for free drug level monitoring: carbamazepine and valproic acid. Ther Drug Monit, 6, 67–76.CrossRefGoogle ScholarPubMed
Keck, P. E., Jr., McElroy, S. L., Bennett, J. A. (1996). Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry, 57 13–18.Google ScholarPubMed
Leppik, I. E., Hovinga, C. A. (2013). Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia, 54, 28–35.CrossRefGoogle ScholarPubMed
Plenge, P., Stensgaard, A., Jensen, H. V., et al. (1994). 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry, 36, 511–516.CrossRefGoogle ScholarPubMed
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 1138–1143.CrossRefGoogle ScholarPubMed
Malhi, G. S., Gessler, D., Outhred, T. (2017). The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord, 217, 266–280.CrossRefGoogle ScholarPubMed
Chouinard, G. (2004). Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry, 65, 7–12.Google ScholarPubMed
Amodeo, G., Fagiolini, A., Sachs, G., et al. (2017). Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets, 16, 885–890.Google ScholarPubMed
Liu, J., Chan, T. C. T., Chong, S. A., et al. (2019). Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry, 14(6), 691–697.CrossRefGoogle ScholarPubMed
Walsh, M. T., Dinan, T. G. (2001). Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand, 104, 84–91.CrossRefGoogle ScholarPubMed
Beach, S. R., Kostis, W. J., Celano, C. M., et al. (2014). Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry, 75, e441–449.CrossRefGoogle ScholarPubMed
Sanchez, C., Reines, E. H., Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol, 29, 185–196.CrossRefGoogle Scholar
Chiu, C. C., Lane, H. Y., Huang, M. C., et al. (2004). Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol, 44, 1385–1390.CrossRefGoogle ScholarPubMed
Asnis, G. M., Thomas, M., Henderson, M. A. (2015). Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci, 17, 1–11.CrossRefGoogle ScholarPubMed
Ozdemir, P. G., Karadag, A. S., Selvi, Y., et al. (2014). Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract, 18, 161–168.CrossRefGoogle ScholarPubMed
Jang, D. H., Manini, A. F., Trueger, N. S., et al. (2010). Status epilepticus and wide-complex tachycardia secondary to diphenhydramine overdose. Clin Toxicol (Phila), 48, 945–948.CrossRefGoogle ScholarPubMed
Tonda, M. E., Guthrie, S. K. (1994). Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy, 14, 543–560.CrossRefGoogle ScholarPubMed
Ogino, S., Miyamoto, S., Miyake, N., et al. (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci, 68, 37–49.CrossRefGoogle ScholarPubMed
Praharaj, S. K., Kongasseri, S., Behere, R. V., et al. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol, 5, 307–313.CrossRefGoogle ScholarPubMed
Morkunas, B., Porritt, K., Stephenson, M. (2016). Experiences of mental health professionals and patients in the use of pro re nata medication in acute adult mental healthcare settings: a systematic review. JBI Database System Rev Implement Rep, 14, 209–250.CrossRefGoogle ScholarPubMed
Maiocchi, L., Bernardi, E. (2013). Optimisation of prescription in patients with long-term treatment-resistant schizophrenia. Australas Psychiatry, 21, 446–448.CrossRefGoogle ScholarPubMed
Remington, G., Addington, D., Honer, W., et al. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry, 62, 604–616.CrossRefGoogle ScholarPubMed
Patterson, T. L., Leeuwenkamp, O. R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res, 100, 108–119.CrossRefGoogle ScholarPubMed
Deutschenbaur, L., Lambert, M., Walter, M., et al. (2014). Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy. Nervenarzt, 85, 363–375.CrossRefGoogle ScholarPubMed